NEW YORK (GenomeWeb News) — Compugen today reported zero revenues for the third quarter as net losses declined 30 percent.
 
Receipts for the three months ended Sept. 30, 2005, were $95,000, Compugen said.
 
R&D spending for the quarter declined 26 percent to $1.7 million from $2.3 million in 2005.
 
Compugen said net losses in the quarter declined 30 percent to $2.5 million  percent from $3.6 million year over year.  
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.